| ACS | Prinzmetal Angina | Stable angina | Unstable Angina & NSTEMI | STEMI |
|---------|--------------------------------------|---|--|---|
| Initial | Risk factors modification. | Risk factors modification: (Smoking cessation, controlling HTN, DM, hyperlipidemia and obesity, diet and exercise) | Acute treatment: -Hospitalization -Nitrates -Oxygen supplement "To improve oxygen supply" -Morphine -Replace deficient electrolytes After acute treatment: <u>Reduce risk factors</u> : (Smoking cessation, weight loss and control DM, HTN and hyperlipidemia) | -Hospitalization Cardiac monitor (CCU) -Nitrates (Nitroglycerine) "Coronary vasodilators > Open artery" -Oxygen supplement "To improve oxygen supply" -Morphine |
| Medical | Calcium channel blockers, Nitrate | Aspirin "reduces morbidity & mortality", Beta-blockers, Nitrates, Calcium channel blocker | -Aspirin -Clopidogrel OR Prasugrel OR Ticagrelor -Beta-blockers (Atenolol OR Metoprolol) -Glycoprotein IIb/IIIa inhibitors (Abcixmab OR Tirofiban) -Heparin OR Enoxaparin "Anti-coagulant > prevent progression of thrombus (decrease mortality)" After acute treatment: Continue Aspirin, Beta blockers and Nitrates. | -Aspirin "Anti-platelets > Reduces coronary reocclusion (Reduces mortality)" -Beta-blockers (Atenolol OR Metoprolol) "Block sympathetic stimulation > Reduces cardiac demand (Reduces mortality)" -ACE inhibitors (Enaloptil OR Usinoptil) "Anti-hypertensive (Reduces mortality)" -Statins "Anti-hyperlipidemic > Lower cholesterol and stabilizes plaque (Reduce risk of further events)" -Clopidogrel "Anti-platelets (In pts undergo PCI)" -Heparin |

| Invasive | 1-Percutaneous coronary | -Coronary angiography & Cardiac | Thrombolysis (fibrinolytics) only in STEMI |
|----------|----------------------------|---|--|
| | intervention PCI | catheterization/Revascularization | (fibrin specific: Alteplase, tPA or non fibrin |
| | (angioplasty): when Two or | -Percutaneous Coronary Intervention | specific: Streptokinase) (Greater benefit in |
| | one vessels occluded. | (PCI) | anterior infarctions) |
| | 2- Coronary Artery Bypass | -90% of patients improve with medical | |
| | Graft: when 3 vessels | regimen and don't need invasive | Percutaneous Coronary Intervention |
| | occluded OR 2 vessels | management. Only if ischemia persist after | (PCI)<90 min (Improve short/long-term |
| | w/diabetes OR Left main | 48 hours, then proceed directly to invasive | outcomes) |
| | artery | procedures. | 1-One vessel occlusion |
| | | | 2-two vessel occlusion |
| | | | 3- no improvement with drugs |
| | | | |
| | | | Coronary Artery Bypass Grafting (CABG): |
| | | | 1-three- vessel occlusion |
| | | | 2-left main coronary artery occlusion |
| | | | 3-left ventricular dysfunction |
| | | | Only if complications OR Failure of PCI |
| | | | Benefits include low rates of events-free |
| | | | survival and reintervention-free survival |

| Arrhythmias | | | | |
|---|---|--|--|--|
| -Bradyarrhythmias | | Tachyarrhythmias | | |
| Sinus Bradycardia | Atropine Blocking the vagal stimulation- | Ventricular Tachycardia | Stable patient: IV Amiodarone, Lidocaine or Procainamide. Unstable patient "Chest pain, SOB, Hypotension and confusion" Synchronized cardioversion. | |
| AV Block (First degree, Second degree Mobitz 1) | No treatment required. | Ventricular Fibrillation | -Immediate defibrillation and CPR,if persistent IV epinephrine or vasopressin If fails antiarrhythmics. -Implantable defibrillator when cardioversion is successful. | |
| AV Block (Second degree Mobitz 2, Third degree) | Pacemaker. | Atrial Flutter | Hemodynamically unstable patient: Synchronized cardioversion (shock) Hemodynamically stable patient: Rate control - Elective cardioversion-, Anticoagulation (depending on CHA2DS2VASc score) - Refer for Ablation | |
| | | paroxysmal Supraventricular Tachycardia | Stimulate vagus delay by carotid sinus massage (or breath holding / head immersion in cold water/ Valsalva maneuver) followed by in stable pt IV Adenosine (act by decreasing SA and AV nodal activity).CCB, b blocker, digoxin (prevention) | |

| | -If episodes are recurrent and symptomatic ⊸ablation is preferred |
|-----------------------------------|--|
| Wolff-Parkinson-White Syndrome | Procainamide (Avoid digoxin / beta blockers /calcium channels blockers) or Radiofrequency catheter 1st line ablation. |
| Multifocal atrial tachycardia | calcium channel blockers, β -blockers, digoxin, amiodarone, IV flecainide, and IV propafenone. If LV function is not preserved, use digoxin, diltiazem, or amiodarone. -Electrical cardioversion is ineffective and should not be used. |
| Atrial fibrillation (AF) | (1)Ventricular rate control. (2)Rhythm control. +Anticoagulation to reduce the risk of stroke in patients with AF >The CHA2DS2VASc Index |

| Acute AF | | | Chronic AF |
|--|--|---|------------|
| Hemodynamically unstable patient | t → immediate electrical cardioversion | A) Rate control: With Beta-blockers or • Ca -channel blockers •Digoxin if BP is low | |
| | Hemodynamically stat | B) Anticoagulation (use CHADSVASc score) Patient with 'lone' AF under age 60 > no need for anticoagulation therapy (low risk of emboli). Treat all other patients with chronic anticoagulation (warfarin). | |
| Prevention of Thromboembolism "Stroke"(Depending on CHADVASc) | Control of Heart Rate | Maintenance of Sinus Rhythm | |
| AF present>48 hours, risk of embolization during cardioversion is significant. Anticoagulate patient for 3 weeks before and 4 weeks after cardioversion -To avoid waiting 3 weeks for anticoagulation, obtain a TEE to image the left atrium, if no thrombus is present, start IV heparin and perform cardioversion within 24 hours -An INR of 2 to 3 is the anticoagulation range | Determine the pulse in a patient with AF. if its too rapid, it must be treated | Use pharmacological cardioversion only if electrical cardioversion fails or is not feasible | |
| Pharmaceutical Warfarin, Aspirin Dabigatran, Apixaban Rivaroxaban avoid in renal impairment | Pharmaceutical • Ca-channel blockers In asthmatics • B-blockers In CAD • Digoxin | Pharmaceutical: most effective when initiated (within 7 days of AF onset). •Antiarrhythmic drugs - Class IA / IC - Class III: e.g. Amiodarone (elderly) •Flecainide •Propafenone (young) | |
| Non-Pharmaceutical: •Removal/isolation of left atrial appendage e.g. WATCHMAN device or surgery | Non-Pharmaceutical •Ablate/Pacing | Non-Pharmaceutical •Ablation •Surgery (MAZE) -Electrical shocks Direct-current cardioversion | |

| Valvular heart disease | Medical | surgical |
|------------------------|---|--|
| Aortic Stenosis | Limited role | Aortic valve replacement Treatment of choice "indicated in symptomatic patients |
| Aortic Regurgitation | Asymptomatic: Medical therapy Serial echo check ups, salt restriction, diuretics,Vasodilators, afterload reduction "ACEI, arteriodilators",digoxin | Symptomatic: Aortic valve replacement Acute Aortic Regur: Medical emergency, perform emergent valve replacement |
| Mitral Stenosis | Diuretics (for pulmonary congestion and edema) oBeta blockers for palpitation and to decrease heart rate. oIf the patient has A-Fib treat them accordingly (digoxin and warfarin) | Percutaneous balloon valvuloplasty Open commissurotomy |
| Mitral Regurgitation | Preload reduction therapy: vasodilators Start with ACE inhibitors if the patient has a cough go for AR Blockers still can't tolerate go for hydralazine Chronic anticoagulant if A-Fib is present OIABP as bridge to surgery for acute MR | oMitral valve repair or replacement (performed before left ventricular function is too severely compromised) How to assess left ventricular function? -<u>EF<60%</u> ->indication of surgery -End Ventricular Systolic Diameter : <u>EVSD> 40mm</u> ->indication of surgery |
| Mitral Prolapse | Beta blockers for chest pain Aspirin (TIA) | |

| Acute rheumatic fever | | | | |
|--|------------------------------------|--|--|--|
| arthritis | Improve with salicylates (aspirin) | | | |
| | Bed rest | | | |
| streptococcal infection | Antibiotics (penicillin) | To avoid recurrent RF and damage the heart. If allergic give (erythromycin / | | |
| ARF Salicylates: Aspirin 75-100 mg /kg/day given as 4 di oAttain a blood level 20-30 mg/d | | 75-100 mg /kg/day given as 4 divided doses for 6 -8 weeks | | |
| | Prednisolone "corticosteroids" | 2mg/kg/day taper over 6 weeks, Given when there is severe carditis. | | |
| Complications Tx | Diuretics, ACEI | Heart Failure | | |
| | Valve replacement | Symptoms develop or LV dysfunction (valvular problems) | | |

| Prevention of RF | |
|-----------------------|--|
| Primordial Prevention | Social; housing, hygiene, overcrowding |
| Primary Prevention | Treatment of Sore Throat. |

| Secondary Prevention | Monthly Penicillin (Benzathine penicillin G IM, Penicillin V Oral, Sulfadiazine Oral) if penicillin & sulfadiazine |
|----------------------|--|
| | allergic so give (Erthromycin) |
| Tertiary Prophylaxis | Medications, Balloon Valvuloplasty, Valve Replacement. |

| HF (systolic failure Tx) | Use | MOA | ADRs | Extra |
|--|---|--|--|---|
| loop diuretics (furosemide(lasix),torsemide , bumetanide) thiazide diuretics (hydrochlorothiazide) | Initial therapy in systolic failure & volume overload | relieve the symptoms by↓ preload. Does not reduce the mortality. | | Combination of diuretic and ACEI should be initial Tx in symptomatic pts |
| ACE inhibitors | Initial therapy for left ventricular systolic dysfunction (LVEF less than 40%) | ↓ afterload by vasodilatation and ↓ preload by absorption of the fluid and it reduces the mortality. | angioedema + cough | Switches: -Cough-> ARB -developed hyperkalemia or renal impairment or in pregnant→ Hydralazine(arterial dilator) with isosorbide dinitrate (Venodilator). |
| B-Blockers (metoprolol . bisoprolol . carvedilol) | Stable pt used in class 1,2 and 3 | anti-ischemic, antiarrhythmic, ↓ heart rate (↓ oxygen consumption increasing filling time) & reduced remodeling of the heart → It decreases mortality | | combination of B blockers (MNM: blocked symptoms =asymptomatic) and an ACE inhibitors required for asymptomatic patient with LVEF less than 40% - <u>not given in high heart rate</u> |
| spironolactone(potassium sparing diuretic) | -chronic CHF - aldosterone antagonist used in advance class 3 and 4 only | decreases mortality -prolong survival in selected pts | | developed gynecomastia, impotence (cause its structurally similar to progesterone) switch to eplerenone. |
| Digoxin | | +ve inotropic effect used in severe CHF/ Afib & only relieve symptoms with EF<40%have been continues despite (ACEi, BB, LD and | -Vagotonic, Arrhythmogenic. -toxicity: yellow vision, N/V | |

| | spironolactone) and does not | |
|--|------------------------------|--|
| | improve the mortality. | |

| Acute hF | O2, loop diuretics (furosemide) most important drug that decreases the preload *Best initial therapy |
|----------|--|
| | , nitrate (IV) that decrease the <u>afterload</u> , morphine |
| | -if pulmonary edema continues add dobutamine |
| | don't use ACEI & b blockers |

| lifestyle modification | Correction of reversible causes | devices |
|---|------------------------------------|---|
| Sodium and fluid restriction, Weight loss | Ischemia Valvular heart disease | •ICD (implantable cardiovascular defibrillator)it's |
| ,smoking cessation ,Restrict alcohol and | Thyrotoxicosis, Shunts, Arrhythmia | indicated for patients at least 40 days post-MI, EF <35%, |
| use Exercise program | | and class II or III. |
| | | • Cardiac resynchronization therapy (CRT): biventricular |
| | | pacemaker indications are similar to ICD except these |
| | | patients also have prolonged <u>QRS duration >120 msec</u> |
| | | |

| Diastolic Dysfunction | B-Blockers, diuretics, ACE inhibitors& ARB |
|----------------------------|--|
| | Management of Acute decompensated Heart Failure (Acute Pulmonary edema) |
| Digoxin and spironolactone | Note : If pulmonary edema continuous despite these 4 so should added dobutamine (increased contractility |
| snould NOT be used. | & decrease alterioad) |

Contraindicated Medication on CHF

Metformin : may cause potentially fatal lactic acidosis.

★ Thiazolidinediones (glitazone): causes fluid retention.

- ★ NSAIDs : may increase risk of CHF exacerbation.
- ★ some of **Calcium Channel blockers** : may raises mortality.

| IE | Bactericidal antibiotics |
|--|---|
| Initial therapy (before culture result) | Vancomycin and gentamicin |
| | Resistant organism: add aminoglycoside & extend Tx duration |
| After culture result | |
| Streptococcus viridans | Penicillin: Ceftriaxone (IV penicillin G/ IV amoxicillin) for 4 weeks |
| | or ceftriaxone 2 weeks followed oral amoxicillin 2 weeks |
| Methicillin resistant Staphylococcus Aureus | flucloxacillin |
| Staphylococcus epidermidis or Resistant Staphylococcus/ <u>allergy</u> | Vancomycin |
| Enterococci | ampicillin and gentamicin |
| Fungal | amphotericin and valve replacement |
| Surgery | Indicated in CHF, Uncontrolled infection and Prevention of embolism. |
| Prophylaxis (High risk people: dental procedure) | amoxicillin or ampicillin. If allergic->give clindamycin |

| PE | | Use | Complication |
|--|---|-----------|--|
| Oxygen | | hypoxemia | |
| heparin | -Prevent further clots formation. (Low molecular weight Heparin or unfractionated benarin) | | Bleeding: -Stop heparin infusion -IV protamine sulfate |
| | -should continue for at least 5 days -Platelet count should be monitored at least every 3 d -goal is an APTT of 1.5 to 2.5 times control | | Heparin-induced thrombocytopenia and thrombosis: -Stop-heparin for platelet counts <75,000. -Replace heparin with direct inhibitors of thrombin-like (desirudin, lepirudin, argatroban) / fondaparinux |
| | | | Heparin-induced osteoporosis (therapy >1 mo): -LMWHs may have lower propensity to cause osteoporosis as compared with unfractionated heparin |
| Oral anticoagulant | -Oral anticoagulants are | | • |
| (Started at the same time with the heparin) | continued for 6 weeks to 6 months, -Anticoagulation(Heparin\warfarin) <u>prevents</u> <u>further clot formation</u> | | |
| Warfarin | monitor INR between 2 and 3 -contraindicated in pregnancy | | Bleeding : -Stop therapy. -Administer vitamin K and fresh-frozen plasma |
| Rivaroxaban or dabigatran | No needs to monitor INR and reach the therapeutic effect in several Hours | | |
| Thrombolytics | | | |

| streptokinase | lysis the clots in massive PE | Hemodynamically unstable patient | |
|------------------------|-------------------------------|---|---|
| ,Urokinase,Recombinant | | (hypotension and tachycardia) | |
| tissue-plasminogen | | Right sided Heart failure | |
| activator | | ●hypoxia on 100% O2 | |
| IVC Filter | | -Anticoagulation contraindicated (eg, patients with multiple trauma, active bleeding) Failure of antithrombotic therapy Complications from anticoagulant therapy preclude further use Prophylaxis against embolism from preexisting DVT in patients with poor cardionulmonary reserve or in patients | -filter migration or misplacement, - filter erosion and perforation of IVC wall, and IVC obstruction due to filter thrombosis. |
| | | at high risk to develop DVT. - Patients with recurrent PE undergoing thromboendarterectomy. | |
| Thrombectomy | | | |

| asthma | | |
|----------------------------------|--|--|
| Causing asthma: Extrinsic asthma | Aspirin, NSAID, B-blockers | |
| Conformity test | PFT: Bronchodilation (albuterol) | |
| | Bronchoprovocation test: methacholine (muscarinic agent) or histamine | |
| Mild asthma | Step1: Inhaled short acting B2 agonist (SABA) (albuterol (most common), pirbuterol or levalbuterol). | |
| Moderate asthma | Step2: SABA +long term agent usually low dose Inhaled corticosteroids (ICS)-> (Leukotriene modifiers as montelukast, | |
| | Or Cromolyn (nedocromil) Or theophylline. | |
| Severe asthma | Step3: Add long acting B2 agonists (LABA) such as salmeterol or formoterol to low dose ICS and SABA. | |
| | Step4: Increase the dose of ICS to maximum in addition to LABA and SABA. | |
| | Step5: Add anti-IgE such as omalizumab to LABG , ICS AND SABA. | |
| | Step6: Add oral corticosteroids such prednisone. | |
| Acute exacerbation of asthma | 1-Oxygen | |
| | 2-Inhaled B2 agonist via nebulizer or MDI →Albuterol | |
| | 3-Steroids I.V initially or orally. | |
| | Third line agent includes IV magnesium →helps with bronchospasm in acute cases. | |

| | cough | | | |
|----------------|---|------------------------------|--|--|
| causing | ACE inhibitors | Bradykinin or accumulates | r Substance P increase ⊸metabolized to PGE2 ⊸PGE2 and caused vagal stimulation of cough. | |
| | GERD: Drugs (Theophylline, oral B adrenergic agonists,NSAIDS,ascorbic acid, Calcium channel blockers) | | | |
| | Тх | | | |
| GERD | Proton pump inhibitor (PPI) for minimum 8weeks (ex:Omeprazole)+ pr | okinetic | | |
| | (ex:domperidone or metoclopramide) | | | |
| Postnasal drip | Sinusitis: 1-Antibiotics 2-Nasal corticosteroids. Rhinitis: Avoid irritants but if it was caused by a virus →medical options 1-Antihistamine (Diphenhydramine,promethazine,loratadine) 2- Nasal corticosteroid (beclomethasone, flunisolide), anti leuko (montelukast) 3-Cromolyn Sodium 4-alpha adrenergic agonists(ephedrine, pseudoephedrine) | include: trienes | | |
| ACE inhibitors | Switch to Angiotensin 2 receptor blockers(ARBS) in case of cardiac/ renal problems | | | |
| | -Antitussive medications | | | |
| In acute cough | Dextromethorphan such as e.g. Benylin non-drowsy | | Have no benefit in the cough caused by smoking, asthma, or emphysema. | |
| | | | <u>Contraindicated in children(< 4 years) and in</u> <u>combination with paracetamol</u>. | |

| Menthol | Steam inhalation, it has short duration of action. |
|-------------------------|---|
| Sedating antihistamines | used in nocturnal cough. Major side effect is sleepiness. |
| Codeine and Pholcodine | Not recommended as it has more side effects and less effectiveness comparing to Dextromethorphan. |
| Guaifenesin and water | to improve the effectiveness of antitussive medications. |

| COPD & Bronchiectasis | | | |
|-----------------------|--------------------------------|--|--|
| COPD | stop smoking. | | |
| | Bronchodilators | a.Short acting bronchodilators for mild disease | |
| | | i.Beta 2 agonists: Salbutamol, Terbutaline | |
| | | b.Long acting bronchodilators for moderate to severe disease | |
| | | i.Beta 2 agonists: Salmeterol, Formoterol, Indacaterol | |
| | | ii.inhaled Anticholinergics (muscarinic antagonists) most effective in COPD. This is because it is | |
| | | believed that beta agonists might cause CVS side effects (tachycardia, etc.): Tiotropium bromide | |
| | | c.Oral bronchodilators can be given to patients who cannot inhale efficiently/ refractory COPD | |
| | | i.Theophylline : → Improves mucociliary clearance and central respiratory drive. not commonly used | |
| | | because it has lots of side effects and drug interactions | |
| | Corticosteroids | a.Inhaled corticosteroids do not alter the natural history of the FEV1 decline | |
| | | I. Usually given in combination with long acting beta agonists | |
| | | i. Remember steroids have many side effects such as osteoporosis and Cushing's syndrome | |
| | Pulmonary rehabilitation | Encourage patients to exercise (patients with dyspnea grade 3-5) | |
| | Oxygen therapy | -Improves survival and quality of life in patients -Only in patients with hypoxia/cor pulmonale | |
| | Vaccinations | a.Influenza vaccine yearly b.Strep pneumoniae vaccine every 5-6 years | |
| | Surgery | a. Bullectomy . b. Lung volume reduction surgery (LVRS) → predominantly upper lobe emphysema | |
| Acute | Don't give 100% O ₂ | might cause respiratory depression and worsens the patient's ventilation and acidosis | |
| exacerbation of | first-line therapy. | salbutamol and ipratropium | |
| | Give nebulized short acting | | |
| | anticholinergic agent | | |
| | Oral corticosteroids not | Systemic corticosteroids are used for patients requiring hospitalization (IV methylprednisolone is a | |
| | inhaled | common choice) | |
| | Antibiotics (aminopenicillin | if there is increase in sputum color, volume, purulence, or breathlessness (bacterial infections) | |
| | or macrolide) | | |

| | amoxycillin/Clavulanate, cephalosporin (e.g. cefuroxime), quinolone (ciprofloxacin, lavofloxacin, moxifloxacin) | If worsening 2 out of 3 of the following: i. Shortness of breath ii. Amount of sputum iii. Purulency of sputum |
|----------------|---|--|
| Bronchiectasis | airflow obstruction | treat that same as COPD patients (inhaled bronchodilators and corticosteroids |
| Dionemeetablis | Physiotherapy | helps the patient to get rid of all the sputum in the respiratory tract |
| | Antibiotics | -usually same as COPD (aminopenicillin or macrolide) but usually for longer durations and higher doses -pseudomonas colonization, Nebulized antibiotic therapy (Gentamicin or Tobramycin twice daily - If culture shows Pseudomonas or Staph aureus, antibiotic therapy might be more difficult and should use sensitivity to quide antibiotic therapy |
| | | -Surgical resection of focal lesions may be indicated. |

| Pleural Effusion | | |
|------------------------------------|---|--|
| Causes: Exudative pleural effusion | Drugs: Hydralazine, Cimetidine, Methotrexate (very common) | |
| | Тх | |
| Thoracocentesis | -Uncomplicated pneumonia: antibiotics | |
| | - Hemithorax involved/empyema: tube thoracostomy +/- VATS | |
| | - Malignant effusion: chest tube +/- pleurodesis (sclerosants) / VATS | |
| Transudative effusion | Diuretics and sodium restriction | |
| | Therapeutic thoracentesis (in massive effusion). | |
| Exudative effusion | treat underlying cause. | |
| Parapneumonic effusions | Uncomplicated: antibiotics alone. | |
| | Complicated or empyema: •Chest tube drainage and antibiotics | |
| | •Intrapleural injection of thrombolytic agents (streptokinase or urokinase); may accelerate the drainage. | |
| | Surgical lysis of adhesions may be required. | |

| | Pneumonia | | | | |
|-------------|--------------------------------|--|--|---|--|
| Community- | Out-Patients | Healthy & non Antibiotic past 3 months Macrolides (azithromycin or clarithromycin) or doxycy | | | |
| acquired | | Comorbidity or Antik | piotic past 3 | -Fluoroquinolones (levofloxacin or moxifloxacin) | |
| pneumonia | | months | | -Advanced macrolide + Beta-lactam (Amoxicillin) | |
| | | Continuous 5 days, st | op when patier | nt is afebrile for 48 hours | |
| | In-Patient | Fluoroquinolones | (levofloxacin | or moxifloxacin) Or Ceftriaxone and azithromycin | |
| | Streptococcus Pneumoniae | Penicillin G., Ceftri | axone, Azith | romycin, Levofloxacin, Vancomycin (in allergy) | |
| | Haemophilus Influenzae | -Amoxicillin + Clave | ulanic Acid (A | Augmentin). | |
| | | - Ceftriaxone, Fluc | proquinolone | es (FQ), or(TMP-SMX). | |
| | Pseudomonas Aeruginosa | -Ceftazidime | | | |
| | | -Cefepime, (Pip/Tazo), Amikacin, Tobramycin, Aztreonam, Ciprofloxacin, Carbapenems, or Polymyxin B. | | | |
| | Acinetobacter | Polymyxin B (colistin) or Tigecycline | | | |
| | Coxiella Burnetii (Q-Fever) | Doxycycline, Rifam | pin or hydro | oxychloroquine. | |
| | Chlamydophila Psittaci | 1st: Tetracycline or doxycycline | | | |
| | (Psittacosis) | Alternative: Macrolide. | | | |
| | Francisella Tularensis | Streptomycin | | | |
| | (Tularemia) | | | | |
| | Influenza | -Neuraminidase In | hibitors: Ose | eltamivir/ Tamiflu Zanamivir(Relenza) for→Influenza A, B | |
| | | -Adamantanes: Am H1N1 is resistant to | nantadine / S Adamantanes | Symmetrel Rimantadine / Flumadine for → Influenza A | |
| Hospitality | Antipseudomonal caplaspitn | es | cefepime or | ceftazidime | |
| acquired | Antipseudomonal penicillins | | piperacillin / tasopactem | | |
| pneumonia | Antipseudomonal Carbapene | em | Imipenem (cause seizure), meropenem or doripenem | | |
| Ventilator | Antipseudomonal beta-lacta | m | Cephalospo | rins or penicillin or carbapenem | |
| Associated | Second antipseudomonal age | ent | Aminoglyco | sides or fluoroquinolones | |
| pneumonia | Methicillin- resistant antista | ant antistaphylococcal Vancomycin or linezolid | | | |
| | agent | | | | |

| Diabetic Nephropathy | | | | | |
|----------------------|---|--|--|--|--|
| Management and | Control the glucose level. | | | | |
| Prevention | Lower the BP to 130/80. | | | | |
| | Reduce Cardiovascular risk. (because the atherosclerosis is highly accelerated among DM) | | | | |
| | □RAAS blockade, independent to BP by giving ACEi/ARBs. | | | | |
| | Both ARbs and ACEi can cause hyperkalemia, in the presence of renal artery stenosis it might cause marked deterioration in renal function, after initial dose checkelectrolytes and renal function. Non-dihydropyridine calcium antagonist (diltiazem,verapamil)may be good alternatives. | | | | |
| | □Lower the LDL level to less than 100 mg/dL →give statins if needed. | | | | |
| | □Smoking cessation. | | | | |
| | Lifestyle modification: Weight loss + exercise + dietrestriction (Slat + protein). | | | | |
| | | | | | |

| Hypertension | | | | | | |
|------------------------------|---|--|--|---|--|--|
| Risk Factors | NSAID by salt and water retention through the kidney by inhibiting prostaglandin | | | | | |
| Etiology | Medications: <u>oral cont</u> steroids, tricyclic antid | Medications: <u>oral contraceptives</u> by direct increase of angiotensinogen from the liver., decongestants, estrogen, appetite suppressants, chronic steroids, tricyclic antidepressants (TCAs). | | | | |
| treatment | Choice of therapy depends on 1-Risk factors (mainly age and ethnicity) 2- Cause 3- Respond to initial therapy 4- Comorbid condition | | | | city) 2- Cause 3- Respond to initial therapy 4- Comorbid condition. | |
| | When to treat & what | target? Low risk patients >160/100 target <140/90 Diabetic ,high risk patients and elderly treat when its > 130/80 target < 130-120/80. Moderate to high risk treat > 140/90 | | | :140/90 erly treat when its > 130/80 target < 130-120/80. 0 | |
| | Goal of management i | s to reduce th | e incidence of adver | se cardiovasculai | r events,stroke and heart failure. | |
| 1.Life style modification | Weight loss (low BMI Exercise Tobacco | ●Dietary m cessation + A | anagement salt restr void alcohol consum | iction + less fat a ption ●Stop unne | nd red meat and more vegetables & fruits and potassium. ecessary medications. | |
| 2. Drug Therapy | A. People without any conditions | People without People less than 60y (either b | | | thiazide , Calcium Channel blockers(CCB) , ACEi or ARB | |
| →divided into two | | Black people above 60 y | | | thiazide or (CCB) | |
| 518105 | | Non black people Above than 60y | | 60y | CCB or ACEi or ARB | |
| | B. People with specific condition: | DM | | ACEi or ARB (Inhibit the RAAS) and major side effect is Hyperkalemia, CCB | | |
| | | Hyperthy | roidism | n BB (decrease both CO and Renin release) and has many side effe bradycardia and bronchospasm. | | |
| | | Benign Pro Hypertroph | ostatic Iy | Alpha Blockers (decrease the arteriolar resistance) | | |
| | | Osteoporosis Thiazide (inc | | Thiazide (incre | e (increase the Calcium reabsorption) | |
| | | CHF or CA | CAD BB , ACEi or ARB, Thiazide, Aldosterone antagonist | | ARB, Thiazide, Aldosterone antagonist | |
| | | Pregnant | gnant woman BB (use first) or (| | or CCB or hydralazine or alpha methyldopa | |
| | | Migraine | | BB, CCB | | |

| | | Post Myocardial | BB, ACEi | |
|---|--|-------------------------------|-------------------|--|
| | | Infarction | | |
| | | Chronic kidney disease | ACEi, ARBs, 1 | ⁻ hiazide |
| | | Stroke | CCB +ACEi | |
| Hypertensive crisis | 1- IV labetalol or nitroprusside 2-I V glycerol trinitrate 3-hydralazine 4- I.V sodium nitroprusside | | 9 | Note: Don't lower the BP to normal because my provoke stroke . |
| Other modalities to treat resistant HTN | Hypertension renal denervation → interrupt the renal sympathetic nervous system → stop RAAS system. Implantable device to activated baroreceptor → to reduce BP | | | |
| Refractory HTN causes | 1- Non-adherence to | therapy 2- Inadequate Tx 3- I | Failure to recogr | ize under lying cause |

| Acid Base Balance | | | | | | | |
|-------------------------------|---|---|-----------------------|--|--|--|--|
| Respiratory acidosis | | | | | | | |
| Etiology | CNS Medication such as (C | Commonly sleeping pills, other: morphine, anesthe | tics and narcotics) | | | | |
| Acute Respiratory Acidosis | Causes: Acute drug intoxication | on •narcotics, •sedatives | | | | | |
| treatment | Verify patency of airways. Give supplemental oxygen : If PaO2 is low (<60 mmHg) Treat underlying cause Intubation and mechanical ventilation might be required for: Severe acidosis (PH <7) PaCO2 > 60 or inability to increase PaO2 Mental deterioration Impending respiratory fatigue | | | | | | |
| Respiratory alkalosis | · · · · | | | | | | |
| etioloy | Drugs (aspirin) | Drugs (aspirin) | | | | | |
| Treatment | •Treat the underlying cause. •Breathe into paper bag to recycle the exhaled CO2 (especially who have anxiety). | | | | | | |
| Metabolic acidosis | | | | | | | |
| etiology | 1.High Anion Gap Causes: | Increase Lactate | Correct hypoperfusion | | | | |
| | | Ketoacidosis | Insulin and fluids | | | | |
| | | Uremia Dialysis | | | | | |
| | Oxalic acid Fomepizole, Dialysis | | | | | | |
| | | Formic acid | Fomepizole, Dialysis | | | | |
| | | Salicylates | Alkalinize urine | | | | |
| | 2.Normal Anion Gap | Decreased production of HCO3 | amphotericin | | | | |

| | | Carbonic anhydrase inhibition | Due to diuretics as acetazolamide. | | |
|---------------------|---|---|---|--|--|
| treatment | 1.Treat the underlyingcause. 2.Sodium bicarbonate is sometimes used in severe acidosis (esp. in normal AG acidosis). 3.Mechanical ventilation might be needed if the patient is fatigued (esp. in DKA). | | | | |
| Metabolic alkalosis | | | | | |
| etiology | Saline – Responsive U(cl-) < 20 | | Diuretic use→ These decrease the ECF volume | | |
| treatment | 1.Treat the underlying cause. 2.Give normal saline plus potassi 3.Spironolactone (K+ sparing diu | um in saline responsive ıretic) might be considered in saline resistant. | | | |

| Acute Kidney Injury | | | | | | |
|----------------------|--|---|---|--|--|--|
| NSAIDs | decrease prostaglandins | decrease prostaglandins decrease GFR | | | | |
| ACE inhibitor | decrease angiotensin II \rightarrow c | lecreased hydrostatic pressure in the g | lomerular capillary ⊸decreased GFR | | | |
| Pre- renal | Treat underlying disorder Give Normal Saline to mai Important to stop antihype | ntain euvolemia and restore blood pre rtensive medications. (Eliminate any o | ssure. <u>Normal saline is not given for patients with ascites or edema.</u> ffending agent NSAID or ACEi) | | | |
| Post - renal | Relieving the obstruction You must secure an IV line hypovolemic shock. | in order to replace the fluid that the pa | atient will urinate. IF you did not do so, the patient would lose lots of fluids and would go into | | | |
| Renal- AKI | tubular | Caused by: toxic (Drugs such as | Treatment of ATN is supportive care: | | | |
| | | aminoglycosides, amphotericin B, | → Maintenance of euvolemia (with diuretics, IVF, as necessary). | | | |
| | | lithium, etc) | \rightarrow Avoidance of hypotension. | | | |
| | | Treatment: supportive (correct | → Avoidance of nephrotoxic medications (including NSAIDs and ACE-I). | | | |
| | | BP, avoid nephrotoxic drugs, etc.) | → Dialysis, if necessary. | | | |
| | Rhabdomyolysis treatment is IV calcium gluconate to protect the cardiac membrane, and give with 5% dextrose to push K+ into the cells | | | | | |
| | Contrast nephropathy Decrease the risk of this condition by giving patient IV fluids before and after the exposu to contrast and also avoid nephrotoxic drugs | | | | | |
| | | | -1/2 NS 1 cc/kg/hr 12 hours pre/post | | | |
| | | | - N-acetyle cystein 600 BID pre/post (4 doses) | | | |
| | | | - Monitoring of urine output, Creatinine and electrolytes | | | |
| | | calcium oxalate | Caused by medication that increases oxalic acid level in body (ethylene glycol) | | | |
| | Interstitial | Most commonly caused by drugs (penicillin & NSAIDs, steroids) | Treatment : stop the offending agent (the drug causing this problem), supportive treatment. | | | |
| | Acute | | →General: supportive therapy | | | |
| | Glomerulonephritis | | →Disease specific: Steroid - Immunosuppressive agents - Plasmapheresis | | | |
| When to do dialysis? | 1.Refractory hyperkalemia 3.Refractory volume overlo | 2.Refractory metabolic acidosis ad 4.Symptoms of uremia (uremic p | pericarditis, encephalopathy) | | | |

| Electrolyte imbalance (Na, H2O) | | | |
|---|-----------------------------------|--|--|
| (Heart Failure with reduced Ejection Fraction | ACE inhibitors | | |
| Central Diabetes insipidus | desmopressin | | |
| Nephrogenic Diabetes insipidus | thiazide diuretics | interfere with the kidney's ability to dilute urine \rightarrow NDI patients will pass concentrated urine. | |
| Treatment of hypernatremia | Treat the underly | ing cause | |
| | hypervolemic | give diuretics (furosemide) and D5W to remove excess sodium. Dialyze patients with renal failure. | |
| | hypovolemic | Stabilize him with NS after ⇒that correct the hyponatremia by replacing the free water deficit -1/2 NS, D5W, oral H2O | |
| | euvolemic | replace the free water deficit* and patients with central diabetes insipidus require desmopressin, amiloride for lithium induced NDI | |
| Treatment of hyponatremia | Remember that if myelinolysis) •D | you quickly correct hyponatremia you can damage the CNS (central pontine o not exceed 9 mEq/L in 24 hours (Uptodate) | |
| | symptomatic | 3% hypertonic saline | |
| | asymptomatic | correct slowly, and treat the underlying cause | |
| | Both symptomation antagonist) | c & asymptomatic long term Tx (H2O restriction, demeclocycline (ADH | |

| | Electrolyte imbalance (K, Ca) | | | | |
|---|---|--|--|--|--|
| What keeps the Intracellular K high? | Insulin , Beta agonists enhance the K/Na pump function Beta Blockers inhibit the pump function | | | | |
| Hyperkalemia causes | Potassium-sparing diuretics (spironolactone) ACE inhibitors. Rapid administration of β-blocker. | | | | |
| Hyperkalemia treatment | *If the hyperkalemia is severe, or if ECG changes are present, first give IV calcium. | ✓Calcium stabilizes the resting membrane potential of the myocardial membrane — that is, it decreases membrane excitability. ✓Use caution in giving calcium to patients on digoxin.(Hypercalcemia predisposes the patient to digoxin toxicity.) | | | |
| | Shift potassium into the intracellular compartment | \sqrt{G} lucose and insulin (Glucose alone will stimulate insulin from β -cells, but exogenous insulin is more rapid) Give both to prevent hypoglycemia. | | | |

| | | | √nhaled beta agonist. |
|------------------------|---------------------------------------|----------|---|
| | | | √Sodium bicarbonate |
| | | | -Increases pH level, shifts K+ into cells. |
| | | | -An emergency measure in severe hyperkalemia. |
| | *Remove potassium from the body | / | √Kayexalate—GI potassium exchange resin (Na+ /K+ exchange in GI tract) |
| | | | absorbs K+ in the colon, preventing reabsorption (passed in stool). |
| | | | √Hemodialysis. |
| | | | -Most rapid and effective way of lowering plasma K+. |
| | | | -Reserved for intractable hyperkalemia and for those with renal failure. |
| | | | √Diuretics (furosemide). |
| Hypokalemia causes | Laxatives. Excessive glucocortic | oids | Epinephrine (β 2-agonists) |
| Hypokalemia treatment | Identify and treat the underlying ca | ause. | |
| | *Discontinue any medications that | can aggr | ravate hypokalemia |
| | Oral KCl is the preferred (safest) me | ethod of | replacement and is appropriate in most instances. |
| | IV KCl can be given if hypokalem | nia is | OGive slowly to avoid hyperkalemia. |
| | severe (less than 2.5)or if the pa | tient | OMonitor K+ concentration and monitor cardiac rhythm when giving IV |
| | has arrhythmias secondary to | | potassium. |
| | hypokalemia. | | OInfusion pearls. |
| | | | Maximum infusion rate of 10 mEq/hr in peripheral IV line. |
| | | | Maximum infusion rate of 20 mEg/hr in central line. |
| | | | • May add 1% lidocaine to bag to decrease pain (potassium burns!) |
| | As with calcium, it is difficult to | correct | the potassium level if any hypomagnesemia is not corrected first |
| Hypercalcemia causes & | Causes: thiazide diuretics | Treatr | ment: Increase urinary excretion: |
| treatment | | 1- IV f | luids (NS) |
| | | 2- Diu | retics Inhibit Bone resorntion |
| | | 1_Ricol | hosphonate |
| | | 2 Calci | itanin |
| | Courses la su diverties | | iconini |
| Hypocalcemia causes & | Causes: loop diuretics | reatr | ment: Symptomatic: IV calcium Long term: oral calcium |
| treatment | | | |

| GLOMERULAR DISEASES | | | | | |
|---------------------|---|----------------------------|--|--|--|
| Primary FSGS | Progression to CKD is | | | | |
| | mycophenolate mofetil | do not respond to steroids | | | |
| | Cause: Drugs: Interferon, Pamidronate, Heroin | | | | |

| Secondary FSGS | treat the primary cause and add supportive measures to protect the kidneys, e.g. keeping blood pressure well controlled with ACEi. | not typically treated with Immunosuppression, |
|--|--|--|
| Primary MCD | Corticosteroids plus Cyclophosphamide or cyclosporine and May be Rituximab | In children; typically is |
| Secondary MCD | Cause: Drugs (NSAIDs, Lithium, Sulfasalazine, Pamidronate, D-penicillamine, some antibiotics) | corticosteroid responsive in > 90% |
| | Secondary MN: Mainly target the primary disease that caused MN, and treat the Nephrotic syndrome manifestations | |
| -IgA Nephropathy (Berger diseases) | Most important treatment is to control the blood pressure which also decreases the proteinuria. •Treated in severe diseases with ACE inhibitors and steroids | There is really no effective immunosuppressing therapy except in severe cases where it can be tried. |
| Post streptococcal glomerulonephritis (PSGN) | fluid and sodium restriction with diuretic and hypotensive agents is usually adequate antibiotic might be added depending on case | |
| -Lupus Nephritis | depends on the findings in renal biopsy. It usually involves high degree of immunosuppressing medications. | |
| ANCA vasculitis | immunosuppression that includes corticosteroids and cyclophosphamide. | |
| Anti-GBM antibody disease,(Goodpasture's Syndrome) | If Linear Anti-GBM positive always started immediately to remove the antibodies by Plasmapheresis and preventing further antibodies production by giving heavy immunosuppression that includes corticosteroids and cyclophosphamide. | |

| Chronic Kidney Failure <u>(for only to know treatment skip to last row)</u> | | | |
|---|---|--|--|
| ESRD: advanced CKD (Stage-5) | requiring dialysis or kidney transplantation | | |
| Factors contributing to the | Drugs (NSAID) | | |
| Progression of CKD | | | |
| salt losing nephropathy | require stepwise increases in Nacl and fluid intake. | | |
| Management | | | |
| Nutrition | restriction intake of: -protein; not less than 0.8mg/kg/day -Phosphate -sodium -potassium | | |
| Salt and water retention | -Salt intake restriction "daily Na+ < 100 meq -fluid restriction 1 – 1.5 L/day -Loop diuretics -RAS inhibition (ACEi, ARB) if HTN w proteinuria | | |
| Hyperkalemia | Medications that ↑K+: ACEI, ARB, NSAID, K- sparing diuretics, B-Blockers, andheparin. Treatment of hyperkalemia: -IV calcium gluconate 10 cc of 10% | | |

| | -Followed by 25 ml of 50% dextrose solution with 5-10 units regular insulin | | | |
|--------------------------|--|--|--|--|
| | -B2-adrenergic agonist nebulizer (salbutamol) | | | |
| | -NaHCO3 IV/oral | | | |
| | -calcium resonium or sodium kayexalate to catch the k in the capillaries of the colon and get it into the stool | | | |
| Hyperphosphatemia and | a. Reduce phosphate intake to < 10 mg/kg/day | | | |
| secondary | b. Phosphate binders: Calcium carbonate, Sevelamer (Renagel), Lanthanum carbonate | | | |
| , hyperparathyroidism | c. Vitamin D (Calcitriol) 0.125 mcq/day | | | |
| | -Must be withheld until s. phosphate concentration < 6mg/dl because it may cause severe soft tissue calcifications. | | | |
| | -Vitamin D compounds can cause hypercalcemia and hyperphosphatemia, which may increase coronary calcification, so | | | |
| | parcicalcitrol (Zemplar) is an analogue that inhibits PTH synthesis without elevation of calcium/phos. | | | |
| | d. Indication for parathyroidectomy: | | | |
| | PTH > 800 pg/ml with symptoms of bone disease (myopathy, bone pain) persistent hyperphosphatemia soft tissue | | | |
| | calcifications. | | | |
| Hyperlipidemia | the goal is to keep low density lipoprotein cholesterol < 100 mg/dl by diet control and statin group. | | | |
| Anemia | A. Oral iron | | | |
| | -in non-dialysis patients (CKD stages 1-4): 100-200 mg elemental iron should be given daily in 2-3 days, either one hour | | | |
| | before meals or two hours post. (1 tab Ferrous fumerate, 200 mg contains 66 mg elemental iron) | | | |
| | -In dialysis patients (CKD 5):IV iron should be given as ongoing iron losses tends to be higher | | | |
| | B. IV iron | | | |
| | - 1 gr of iron saccharate (ferrosac) divided into 10 doses of 100 mg given with each <u>dialysis</u> session. | | | |
| | C. Erythropoletin types: Short acting and long acting | | | |
| | → Short acting eprex during hemodialysis | | | |
| | → Long acting Darbepoetin peritoneal dialysis | | | |
| | | | | |
| | Recombinant Erythropoeitin–epoeitin alfa (eprex): | | | |
| | - patients on: starting dose 120 – 180 IU/kg/week, IV | | | |
| | - pre-dialysis patients and PD patients: 80-120 IU/kg/week subcutaneously weekly dose | | | |
| | - Hb/Hct monitoring every 4 weeks | | | |
| | - the most common side effects: headache, HTN, arthralgia, and diarrhea | | | |
| | - resistance to epoeitin: | | | |
| | 1. Inadequate Epo dose | | | |
| | 2. anemia of chronic disease (infection, inflammation) | | | |
| | 3. Tunctional from deliciency | | | |
| | 4. secondary to hyperparathyroidism | | | |
| | 5. carritude denciency | | | |
| | o. nemoglobihopaniles | | | |
| | 8. B12/folgte deficiency | | | |
| | 0. Malautritian | | | |
| | | | | |
| | | | | |

| | D. Darbengetin Alfa (Arapesp) |
|-------------|---|
| | Parembinant Eng |
| | - Recombinance Epo |
| | - Hait-life: three folds longer IV and two folds longer S/C than that of epoetin |
| | - Recommended starting dose 0.45 mcg/kg S/C weekly or double the dose every 2 weeks |
| Medications | Loop diuretics (fursemide) (Salt and water retention). |
| | -RAS inhibition (ACEi, ARB) if HTN with proteinuria . |
| | -Phosphate binders (Calcium carbonate, Sevelamer (Renagel), Lanthanum carbonate), given with meals |
| | Stotic (hyperlinidos) (california) |
| | -Statif (hyperlipticerina). |
| | -Parcicalcitrol (Zemplar)Inhibits PTH synthesis without elevation of Ca2+/PO43- (Vitamin D compounds →Hypercalcemia |
| | + Hyperphosphatemia →coronary calcification). |
| | |
| | Parathyroidectomy when PTH 800 pg/ml + bone disease symptoms (myopathy, bone pain) + persistent hyperphosphatemia |
| | and the second method of the second |
| | Hyperkelemin (temporary protect the beart from arrhythmic by shifting the K i jota the cell); IV coloium glucopate 10 as of |
| | - Typerkalema (temporary protect the heart for armythma by sinting the K+ into the cell). It calculate to cool |
| | $10\% \rightarrow 25$ m of 50% dextrose solution with 5-10 units regular insulin |
| | →B2-adrenergic agonist nebulizer (salbutamol) →NaHCO3 IV/oral. |
| | -Erythropojetin for anemia (Hemoglobin should not go back to normal but around 11-12, if more than 12 high chance of |
| | strokes and cardiac problems) |
| | |
| | Over lyon (400, 200 mg) if not on dislusion (1) (lyon if on Dislusion divided into 40 descent 400 mg given with each dislusion |
| | -Oran from (100-200mg) in not on dialysis, iv from it on Dialysis divided into 10 dosesor 100 mg given with each dialysis |
| | session |

| Acute Viral Hepatitis | | |
|-----------------------|--|--|
| Autoimmune disorder | prednisone and or azathioprine. | |
| Hepatitis A | -Hepatitis A vaccine (pre-exposure) "Active vaccine" - Immunoglobulin (pre- and post-exposure) "passive" resolve spontaneously over a few weeks and are almost always benign conditions | |
| Hepatitis B | -vaccine -only treated <u>chronically</u> with interferon or lamivudine. | |
| Acute hepatitis C | in the few cases in which it is detected, should be treated with Interferon and ribavirin and either boceprevir or telaprevir. | |
| Chronic HCV | Interferon and ribavir in or direct acting anti virus which depends of specific HCV genotype: genotype 1 \rightarrow ledipasvir and sofosbuvir orally for 12 weeks, other genotypes include \rightarrow sofosbuvir and ribavir orally. | |

| | Gastrointestinal Bleeding | | | |
|---------------------------------|---|--|--|--|
| Always ask patient if they take | NSAIDs/aspirin, clopidogrel or anticoagulants | | | |
| Steps of management | | | | |
| 1- Hemodynamic status and | •IV fluid resuscitation [initial assessment]. | | | |
| resuscitation | Supplemental oxygen. | | | |
| | Draw blood for hemoglobin and hematocrit, PT, PTT and platelet count | | | |
| | Monitor the hemoglobin every 4 to 8 hours until the patient is hemoglobin stable for at least 24 hours. | | | |
| | Has been shown to significantly decrease mortality. | | | |
| 2-Blood transfusion | Type and crossmatch adequate blood | | | |
| | Don't rush into transfusion | | | |
| | Should be administered to a patient with a hemoglobin level of 70 g/L or less | | | |
| | Rarely indicated when the level is > 100 g/L | | | |
| | • <u>Almost always indicated when the level is < 60 g/L.</u> | | | |
| | •Target level of 70 to 90 g/L | | | |
| | • The role of transfusion in clinically stable patient with mild GI bleeding remains controversial, with uncertainty at which | | | |
| | hemoglobin level transfusion should be initiated. | | | |
| | •The restrictive RBCs transfusion had significantly improved survival and reduced rebreeding. | | | |
| | • I ransfusion as the clinical demands: <u>shock, patient with cardiopulmonary disease</u> . | | | |
| 3-Risk stratification | A. Low vs. high risk | | | |
| | B. Early identification | | | |
| | C. Appropriate intervention | | | |
| | D. Minimizes morbiolity and mortality | | | |
| 4-Pre-endoscopic therapy | Nasogastric tube: Evaluvation of aspirate PPI treatment before endoscopy | | | |
| 5-Endoscopic therapy | Timing of endoscopy: •Definition of early endoscopy Ranges from 2 to 24 hours AFTER INITIAL PRESENTATION | | | |
| | May need to be delayed or deferred: | | | |
| | oActive acute coronary syndromes oSuspected perforation | | | |
| 6-Post-endoscopy | •PPIs: | | | |
| | | | | |
| | •Has no benefit on overall mortality (improve mortality if patients at highest risk) | | | |
| | oIntermittent PPI (IV boluses) therapy is comparable to the recommended continuous IV infusion in patients with High risk | | | |
| | bleeding ulcers. | | | |
| | •There is no difference in clinical outcomes between oral and intravenous PPI. | | | |
| | ○Patients receiving oral PPI have a shorter hospital stay. → Compared to H2Ras with or without endoscopic therapy they | | | |
| | reduce: rebleeding, surgery but not mortality | | | |
| Hospitalization | •It takes 72 hours for most high-risk lesions to become low-risk lesions AFTER endoscopic therapy. | | | |
| | •60% - 76% of patients who had rebleeding within 30 days AFTER endoscopic hemostasis PLUS high-dose PPI therapy did | | | |
| | so within the first 72 hours. | | | |

| ICU | For at least the first 24 hours on the basis of risk or clinical condition: | | | |
|--------------------------|--|--|--|--|
| | -Hemodynamic instability | | | |
| | -Increasing age | | | |
| | -Severe comorbidity | | | |
| | -Active bleeding at endoscopy | | | |
| | -Large ulcer size (>2 cm) | | | |
| After discharge | a prescription for a single daily-dose oral PPI for a duration as dictated by the underlying etiology. | | | |
| Management of continued | Percutaneous or trans catheter arterial embolization | | | |
| or recurrent bleeding | •Technical success range from 52% to 98% •Recurrent bleeding in about 10% to 20% | | | |
| | Complications include: | | | |
| | -Bowel ischemia | | | |
| | -Secondary duodenal stenosis | | | |
| | -Gastric, hepatic, and splenic infarction | | | |
| | A second attempt at endoscopic therapy remains the preferred strategy | | | |
| | oAngiography: | | | |
| | Where available, percutaneous embolization can be considered as an alternative to surgery for patients for whom endoscopic | | | |
| | therapy has failed. | | | |
| Management of Esophageal | 1. Patients with medium/large varices: Beta blockers (Propranolol, nadolol) or Endoscopic variceal ligation | | | |
| varices | 2. Patients with high-risk small varices: Beta blockers | | | |
| | 3. Patients with small varices without signs of increased risk: Beta blockers | | | |
| H pylori | Patients with bleeding peptic ulcers should be tested for H. pylori | | | |
| | -Receive eradication therapy if present -Confirmation of eradication | | | |
| | Negative H. pylori diagnostic tests obtained in the acute setting <u>should be repeated</u> | | | |
| When to do surgery | •Hemodynamically unstable patients who have not responded to IV fluid, transfusion, endoscopic interventions, or correction of | | | |
| | coagulopathies. | | | |
| | Sever initial bleed or recurrence of bleed after endoscopic treatment. | | | |
| | •Continued bleeding for more than 24 hours. | | | |
| | Visible vessel at base of ulcer (30% to 50% chance of rebleed). | | | |
| | Ongoing transfusion requirement (five units within first 4 to 6 hours) | | | |

| kkJaundice (causes) | |
|--|---|
| Unconjugated Hyperbilirubinemia (indirect) | Drugs such as rifampicin, penicillin, sulfonamide and radiocontrast agent |
| Conjugated Hyperbilirubinemia (direct) | Drug induced: Oral contraceptive, Tylenol OD, idiosyncratic reaction or toxins as cocain. |

| Liver Cirrhosis | | | | |
|--------------------------------|---|---|---|--|
| Varicosity of veins | (Active bleeding) | | | |
| (esophageal & gastric) | ABC | IV fluids (normal saline) to maintair plasma if PT or INT is high. | n BP , PRBC if hemoglobin level is low , platelets if low , | |
| | IV prophylactic antibiotic | (ceftriaxone or ciprofloxacin) : to prevent infection because bleeding is good media to bacteria | | |
| variceal without bleeding: | IV vasopressin | octreotide or somatostatin 3 to 5 days. It causes vasoconstriction of the splanchnic vessels -the varices to collapse. | | |
| BB (propranolol or | upper GI endoscopy | either Endoscopic variceal ligation (EVL) or Endoscopic sclerotherapy | | |
| nadolol) | Nonselective BB (propranolol or nadolol) | to prevent recurrence of bleeding | | |
| | Transjugular intrahepatic | artificial channel <u>between portal sys</u> the bleeding | stem and hepatic vein used If the above drugs can't control | |
| | portosystemic shunt (TIPS) | | | |
| ASCITES | Treat the underlying cau | se | Treatment of refractory ascites ~10% | |
| | •Salt dietary restriction | | 1. Serial therapeutic paracenteses + intravenous infusion | |
| | Diuretics (Combination of a Result reprint temping is done | of Spironolactone and Furosemide) | of albumin if draining > 5L fluid | |
| | TIPS : done when asites not respond to above TIPS : done when asites not respond Recurrent tapping Liver transplantation : last option when asites cannot control | | 2. Transjugular intrahepatic portosystemic shunt | |
| | | | 3. Liver transplantation | |
| | | | 4. Peritoneovenous shunt | |
| Spontaneous | V third generation cephalosporin (ceftriaxone or cefotaxime) | | | |
| bacterial peritonitis (SBP) | ●Albumin | | | |
| Hepatic | Exacerbation factors | Drugs (like narcotics and , diuretics | sedative drugs.) | |
| encephalopathy | Treatment | •Lactulose (First line of treatment) : changes the colonic PH, making it acidic by forming | | |
| | | NH4 \rightarrow prevents absorption of ammonia and promote excretion . | | |
| | | •Rifaximin/ metronidazole: kills the | flora \rightarrow decrease the ammonia production | |
| Hepatorenal | •Correct underlying cause | ct underlying cause • Albumin | | |
| synarome | Vasoconstrictors of spla | s of splanchnic vessels (Terlipressin, octreotide, midodrine, epinephrine) | | |
| | HD (Hemodialysis) | •Liver Transplantation in (deco | mpensated cirrhosis) | |
| Hepatocellular | Different scoring systems | ferent scoring systems, Famous system(Barcelona Clinic Liver Cancer Staging Classification (BCLC) | | |
| carcinoma | 1. Liver Transplantation | Transplantation 2. Surgical resection 3. Ablation (alcohol, RFA, Microwave) | | |
| (nepatoma) | 4. Transarterial chemoem | bolization or Radioembolization (inje | ection of a chemotherapeutic agent and lipiodol into the | |
| | hepatic artery) | 5. Systemic therapy (very limited ro | ole) | |
| Coagulopathy | Fresh frozen plasma | | | |

| Management of IBD | | | | |
|---|--|--|---|---|
| 1.Medical Therapy | Drugs | MOA | use | Side effects |
| 5-ASA (5-aminosalicylic acid compounds or aminosalicylates) | Sulfasalazine, Mesalamine compounds Oral (Asacol, pentasa. Rectal(Canasa, Rowasa) | Induce and maintain remission by anti- inflammatory effect (inhibit prostaglandins and leukotrienes) | | (of sulfasalazine): Crystalluria ,BM depression, Megaloblastic anemia,Folic acid deficiency |
| Metronidazole | | | if no response to 5-ASA | |
| Corticosteroids | Systemic:Prednisolone. Local (rectal): Budesonide | | Acute exacerbation and if there is no response to metronidazole (used to Induce remission) | |
| Immunomodulators | Azathioprine methotrexate | Azathioprine "Inhibit purine synthesis", methotrexate "folic acid antagonist" | in conjunction with steroids if the patient does not respond to the previous drugs | |
| Anti-TNF therapy | infliximab, Adalimumab, Certolizumab | Inhibit TNF- α and it has higher response in CD than UC | in fistula or severe disorder unresponsiveness to | |
| 2. Nutrition therapy(crohn's) | Bile acid sequestrant (chole | styramine, colestipol) | | |
| 3. SURGICAL THERAPY | Used For complications ,Fa | lure of medical therapy and S section with anastomosis | Severe disability □ UC ⊸total resection | |

| Dysphagia | | |
|-------------|------------------------|---|
| Achalasia | Drugs | Antimuscarinic agents / Nitroglycerin / Calcium channel blockers |
| | Endoscopic | effective in 80-85% of patients thus the treatment of choice |
| | (Pneumatic) dilatation | |
| | Botulinum toxin | |
| | injection | |
| | Surgical | Surgical sectioning / Heller myotomy |
| Esophageal | Zenker | Surgery: Cricopharyngeal myotomy/ Diverticulectomy is of secondary importance |
| diverticula | epiphrenic | Surgery: Esophagomyotomy / Diverticulectomy is of secondary importance. |

| GERD | Major factors | drugs (eg: Anticholinergics, Calcium Channel blockers & Nitrates), |
|------------|-----------------------------|--|
| | treatment | A- PPIs, which are usually effective in resolving symptoms and healing esophagitis |
| | | B- domperidone, when dysmotility features are prominent |
| | | C- antacids and alginates can also provide symptomatic benefit |
| | | D- H2-receptor antagonist drugs also help resolving symptoms without healing esophagitis |
| | Barrett's esophagus | 1-Endoscopic therapies, such as: |
| | | radiofrequency ablation or photodynamic therapy used only for those with dysplasia or intraconal cancer like patients with CLO without dysplasia should undergo endoscopy at 3– 5-yearly intervals |
| | | low-grade dysplasia at 6–12-monthly intervals |
| | | 2- esophagectomy or endoscopic therapy with a combination of endoscopic resection(ER) For those with high-grade dysplasia (HGD) or intraconal carcinoma. |
| | Benign esophageal stricture | long-term therapy with a PPI drug |
| Esophageal | Tx | 1. Palliation is the goal in most patients |
| Cancer | | 2. Surgery (esophagectomy) |
| | | Chemotherapy plus radiation before surgery has been shown to prolong survival more than surgery alone. |

| Abdominal pain & IBS | | | | |
|---|---|--|--|--|
| Abdominal pain | History: Medication | History: Medications (aspirin or NSAIDs) | | |
| Peptic Ulcer | Acid suppression: - H2 blockers "accelerate healing of ulcer" - PPIs. (most effective) - Antacids. "Symptomatic relief" • Eradicate H. pylori: - With triple or quadruple therapy (PPI, bismuth and 2 antibiotics). • Cytoprotection: - Sucralfate, "facilitates ulcer healing," - Misoprostol, "Can cause GI upset (common side effect)" | | | |
| Acute pancreatitis | Causes D Treatment If | Drugs : diuretics, NSAIDs NPO •IV hydration •Painkiller f more than 30% of the pancreas is <u>necrosed</u> , prophylactic antibiotics (imipenem | | |
| IRRITABLE BOWEL SYNDROME (IBS) Management | •Fiber and diet • •Anti Motility : □ di •Tegaserod maleate (| Anti spasmodic agent (hyoscyamine or dicyclomine) •Tricyclic and antidepressant iarrhea -Loperamide □ Constitution -cisapride Zelnorm) is a serotonin agonist recently introduced for the treatment of IBS | | |

Chronic diarrhea & Malabsorption

| Malabsorption | Treatment of | •A gluten-free diet helps treat celiac disease. |
|---------------|---------------|--|
| тх | causative | ●Similarly, a lactose-free diet |
| | disease | Protease and lipase supplements are the therapy for <u>pancreatic insufficiency</u>. |
| | uiscuse | Corticosteroids, anti-inflammatory agents, such as mesalamine, and other therapies are used to treat |
| | | <u>Crohn's</u> |
| | | • <u>Whipple disease</u> : 2 weeks with Antibiotics to cross BBB:Ceftriaxone, or Penicillin G + streptomycin |
| | | - THEN Septra 1 year (Trimethoprim/sulfamethoxazole) |
| | | •SBBO: Metronidazole, Amox/Clav, Tetracycline, Doxycycline, Amoxicillin (May need to cycle Abx to |
| | | avoid resistance) |
| | | - Bowel cleanse with PEG (Polyethylene glycol) |
| | | -Prokinetic to stimulate motility > bacterial cleansing |
| | | Octreotide – at low dose, has a promotility effect; (causes hypomotility at higher doses) |
| | | - Probiotics – minimal evidence |
| | | •Tropical Sprue: 1) Folate & B12 Supplement 2) Tetracycline for 3-6 months. |
| | | •Bile Acid-Induced Diarrhea: Cholestyramine (it binds to bile acids thus reducing its irritant effects) |
| | Nutritional | Supplementing various minerals calcium, magnesium, iron, and vitamins. |
| | support | •Caloric and protein replacement also is essential. |
| | | Medium-chain triglycerides can be used for lymphatic obstruction. |
| | | •In severe intestinal disease, such as massive resection and extensive regional enteritis, parenteral nutrition . |
| Chronic | Osmotic | Caused by: osmotic laxatives |
| diarrnea | Carcinoid | therapy is octreotide |
| | Ab associated | Clindamycin or any Ab + C.diff |
| | diarrhea | |
| | Treatment | >Rehydrate; monitor electrolytes and replace if necessary |
| | | >Treat the underlying cause (stop or change the medication, advice lactose free diet). Consider atrial of NPO. |
| | | ≻Consider antibiotics in infectious diarrhea→5 day course of ciprofloxacin. Antibiotics are definitely |
| | | recommended in these following conditions: |
| | | •Patients has fever, bloody stools, or severe diarrhea- give quinolones. |
| | | Positive stool culture |
| | | Patients has traveler s diarrhea. C. Difficile infection. Cive Metropidezele |
| | | •C.Difficite infection: Give Metrofficazole. |
| | | ➤_operamide (imodium) is an antidiarrheal agent that should only be given is mild to moderate and not |
| | | recommended in patient with fever of bloody diarrhea. |

Fatima Alddin